Personalizing Curative Therapy in Stage II to III Triple-Negative Breast Cancer
American Society of Clinical Oncology Educational Book · 2026-06 · 46 (3)
DOI: 10.1200/edbk-26-520834 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2026-06. Verfasst von Alexis LeVee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Precision Medicine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 138 Literaturangaben.
Abstract (Originalsprache)
The treatment paradigm of stage II to III triple-negative breast cancer (TNBC) is rapidly evolving, with the recent incorporation of pembrolizumab to neoadjuvant chemotherapy improving disease outcomes. Nevertheless, almost one in five patients with early-stage TNBC will relapse in 5 years, underscoring an urgent need to identify and improve outcomes for those at high risk of recurrence. Novel therapeutic strategies including antibody-drug conjugates, anti-vascular endothelial growth factor therapies, dual immune checkpoint blockade, and locoregional therapies to augment the antitumor immune response are being investigated in clinical trials. Biomarker strategies including tumor infiltrating lymphocytes, immune signatures, and circulating tumor DNA are being explored to identify patients at a high risk of relapse and to predict treatment response. In this article, we review recent advances in the management of stage II to III TNBC, highlight emerging investigational therapies and combinations, and explore novel biomarker strategies aimed at personalizing the care for patients with stage II to III TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA.
- Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL.
- Division of Oncology, Department of Oncology, Mayo Clinic, Rochester, MN.
- Department of Medical Oncology, University of Texas Southwestern Medical Center, Dallas, TX.
ORCID-Profile: Heather McArthur
Zitieren
APA
LeVee, A., Hennessy, M. A., Idossa, D., Leon-Ferre, R. A., Nanda, R., & McArthur, H. (2026). Personalizing Curative Therapy in Stage II to III Triple-Negative Breast Cancer. American Society of Clinical Oncology Educational Book, 46(3). https://doi.org/10.1200/edbk-26-520834
Vancouver
LeVee A, Hennessy MA, Idossa D, Leon-Ferre RA, Nanda R, McArthur H. Personalizing Curative Therapy in Stage II to III Triple-Negative Breast Cancer. American Society of Clinical Oncology Educational Book. 2026;46(3). doi:10.1200/edbk-26-520834
BibTeX
@article{LeVee2026,
author = {LeVee, Alexis and Hennessy, Maeve A and Idossa, Dame and Leon-Ferre, Roberto A and Nanda, Rita and McArthur, Heather},
title = {Personalizing Curative Therapy in Stage II to III Triple-Negative Breast Cancer},
journal = {American Society of Clinical Oncology Educational Book},
year = {2026},
volume = {46},
number = {3},
doi = {10.1200/edbk-26-520834}
}
EUVIMED